TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Forced spirometry
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Pulse oxymetry
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in zinc and selenium status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Days on antibiotics
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Premature ventricular contractions (PVCs) measured by EKG
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change from baseline in the Hospital anxiety and depression scale (HADS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: COVID-19 Infection
Endpoint domain: Adverse events/effects
Primary endpoint: improvement in cyclical breast pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Reduce stress and anxiety
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Post operative infection
Endpoint domain: Adverse events/effects
Primary endpoint: Primary Ovarian Insufficiency Normogram
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Gain in Specificity at Fixed 98% Sensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: resuscitation skill performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of intracranial hemorrhagic complications
Endpoint domain: Adverse events/effects
Primary endpoint: Neurobehavioural outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: tolerability assessment
Endpoint domain: Adverse events/effects
Primary endpoint: Wound incision time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change in self reported pain scores
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Change in self reported mobility scores
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Satisfaction With CALM Sessions
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Helpfulness of CALM Sessions
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of Participants Likely to Recommend the Program to Others
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Proportion of women who successfully receive the MLPTs
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Proportion of women who use the MLPTs to determine their abortion outcome
Endpoint domain: Life impact
Endpoint subdomain: Decision-making
Primary endpoint: Proportion of women who are satisfied with using MLPTs
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: All cause mortality within 30 days
Endpoint domain: Mortality/survival
Primary endpoint: Detection of early progression to Tumor
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: adherence to physical therapy exercise
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Pharmacodynamic Effect
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under The Observed Plasma Concentration-Time Curve Between Dosing Intervals AUC(0-tau)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Observed Plasma Concentration (Cmax) of Ganciclovir
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Chronic Kidney Disease Knowledge
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Acromegaly quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: 90 days adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Diagnostic accuracy of Seated Saline Suppression Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of bowel movements/day
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change From Baseline in the Frequency of Satisfying Sexual Events (SSE)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change From Baseline in the Monthly Sum of Responses to the Daily Desire Question
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Percent change in plasma LDL-cholesterol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Discharged
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Annual Growth Rate Standard Deviation Score (SDS) for Chronological Age (CA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fetal Myocardial Performance Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage of women with an intra-uterine pregnancy with positive embryo heart-beat
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Arrest of dental caries
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: E-cigarette use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Healthy days (health-related quality of life)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: change in exercise performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: current use of a modern family method
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: immediate uptake of a modern family planning method
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Laser Doppler Flux Index Primary Peak
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Overall Neuropathy Limitations Score (ONLS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Adenoma detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Percentage of Participants With a Failed Voiding Trial
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Number of Abnormal Laboratory Measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrease in ICP during IHE episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Circumcision status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: remission
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: MPI Summed Stress Scores for extent and severity of disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Temporomandibular joint space measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Symptomatic confirmed deep venous thrombosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Symptomatic confirmed pulmonary embolism
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Pattern of local anaesthetic spread
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change From Baseline in Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Total Neutrophils, Platelet Count, White Blood Cell (WBC) Count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of follow-up visits
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change in visceral fat area at L4 from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Changes in putatively identified plasma metabolites (Normalized peak intensities) from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Successful voiding in initial period
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: No relapse during the 6 month treatment period
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: No need / indication for surgery during the initial or 6 month treatment periods
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Wender Reimherr Adult Attention Deficit Disorder Scale
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Innate immune cell assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: change in dry eye testing measures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in dry eye symptoms
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Metabolomic Profile Change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: clinical response to cetuximab-based treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bacterial re-infection within 28 days
Endpoint domain: Adverse events/effects
Primary endpoint: Change in the Simpson-Angus Extrapyramidal Symptoms Scale (SAS) scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in the Barnes Akathisia Rating Scale (BAS, BARS) scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in the Abnormal Involuntary Movement Scale (AIMS) scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Reversibility of psychological markers of pain processing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Predictive error (Cpred-Cobs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reaching the target concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of MAAEs and SAEs
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence and severity of solicited local reactogenicity AEs
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence and severity of solicited systemic reactogenicity AEs
Endpoint domain: Adverse events/effects
Primary endpoint: Length of respiratory support
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in blood flow in the brain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Symptom Assessment iN Dry Eye (SANDE) Frequency Score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Symptom Assessment iN Dry Eye (SANDE) Severity Score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Corneal Fluorescein Staining Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ad libitum intake of the test meals - calories (kcal)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of the Boston Carpal Tunnel Questionnaire (BCTQ)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change from baseline of inner arm skin laxity clinical grade
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change from baseline of inner arm skin roughness clinical grade
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change from baseline of inner thigh skin laxity clinical grade
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change from baseline of inner thigh skin roughness clinical grade
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change from baseline of inner knee skin laxity clinical grade
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: % ILC2 cells among total blood lymphocytes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Improvement in exacerbation rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Proportion of patients successfully completing the entire treatment plan
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: British Isles Lupus Assessment Group Index-based Combined Lupus Assessment (BICLA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Autonomic activity variability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Development of migraine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Interstitial Adenosine Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With IGA 0/1 and Decrease in IGA of ≥2 Points
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of Survival
Endpoint domain: Mortality/survival
Primary endpoint: Percentage of women reaching Mg therapeutic level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Symptom relief (abdominal pain)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Symptom relief (stool consistency)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: IL-1 and IL-6 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Serum concentrations of SAR231893 (REGN668)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CKD metabolic control score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Safety of inhaled nitric oxide delivery
Endpoint domain: Adverse events/effects
Primary endpoint: Hand Sweating Severity Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: IL-17 and IL-23 producing cells in blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: IL-17 and IL-23 coding mRNA in intestinal biopsies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Clinical and hematological response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Red Blood Cell Folate Concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of examinations with correctly set threshold algorithm lines
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Distant-metastasis-free survival
Endpoint domain: Mortality/survival
Primary endpoint: Percentage of Participants Achieving Serum Bactericidal Assay Using Human Complement (hSBA) Titer Level >= Lower Limit of Quantitation (LLOQ)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With Fold Rise >=4 in hSBA for Each of the 4 Primary MenB Test Strains
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of genetic variants associated with invasive streptococcal infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Time to reduce tympanic temperature to < 34C
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Isometric knee extension torque
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Average depths of hypnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of VRS nausea
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Regions With Collateral Versus Antegrade Blood Flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in EQ-5D-5L index
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in Zurich Claudication Questionnaire (ZCQ)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Thermal Pain Threshold (TPT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Thermal Pain Tolerance (TPTol)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Elbow Extension ROM Obtained on Neurodynamic Testing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: percent coefficient of fat absorption (% CFA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Plasma concentration of antiinfective agents
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: DMFT (Decayed, Missing, Filled Teeth)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in lung toxicity (DLCO)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Tolerated dose of preoperative hyperfractionated radiation and concurrent chemotherapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Risk of heterosexual HIV transmission
Endpoint domain: Adverse events/effects
Primary endpoint: Clinical evaluation during hospitalization
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Subjects With Vaccine Response Against Pertussis Toxoid, FHA and PRN Antigens
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Seroprotected Subjects With Anti-diphtheria and Anti-tetanus Antibody Concentration Above or Equal to the Assay Cut-off
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Seroprotected Subjects With Anti Hepatitis B Antibody Concentration Above or Equal to the Assay Cut-off
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Seroprotected Subjects With Anti-poliovirus Type 1, 2 and 3 Antibody Concentration Above or Equal to 8
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Normalization of serum cholesterol concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: child development
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: maternal psychosocial distress/depression
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Percentage of Participants With UC Achieving Clinical Response Based on Partial Mayo Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With CD Achieving Clinical Response Based on Harvey-Bradshaw Index (HBI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Bio-naïve Participants Reporting One or More Treatment-emergent Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Patient Score on QoR40 Inventory
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Patients' knowledge about clinical trials
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Distance estimated by the 6 minutes Walk Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pre-operative global longitudinal strain rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of subjects with Kawasaki Disease and concomitant SARS-COV-2 infection
Endpoint domain: Mortality/survival
Primary endpoint: Phosphocreatine Recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Clinical profile specific to Huntington's disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent flow rate reduction of study catheters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HIV specific cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: CD4-CD8 non specific cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Chest CT scan features
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: percent tumor shrinkage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: GH and IGF-I age-normalized levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: percent GH and IGF-I suppression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change in tissue levels of the proliferation marker Ki-67
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety as determined by adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Time of delivery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Change From Baseline in GAD Symptomatology
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: body weight loss of more than 5%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: body weight loss of more than 10%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of Participants Until First Non-detectable SARS-CoV-2 in Nasopharyngeal (NP) Swabs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes